Patents by Inventor Gary SAMORISKI

Gary SAMORISKI has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS OF TREATING CNS DISORDERS
    Publication number: 20120046302
    Abstract: The present invention relates to methods of treating various CNS disorders, e.g., mania, bipolar disorder and schizophrenia, by administering NMDA receptor antagonists, alone or in combination with dopamine receptor antagonists.
    Type: Application
    Filed: February 11, 2011
    Publication date: February 23, 2012
    Inventors: Kelly Papadakis, Nika Adham, Gary Samoriski
  • PHARMACEUTICAL COMPOSITIONS CONTAINING DOPAMINE RECEPTOR LIGANDS AND METHODS OF TREATMENT USING DOPAMINE RECEPTOR LIGANDS
    Publication number: 20120028991
    Abstract: The present invention relates to pharmaceutical compositions containing dopamine receptor ligands and selective serotonin reuptake inhibitors and to methods of treating disorders such as schizophrenia, major depressive disorder and bipolar depression using combinations of dopamine receptor ligands and selective serotonin reuptake inhibitors. The present invention also relates to methods of treating depression using dopamine receptor ligands.
    Type: Application
    Filed: October 10, 2011
    Publication date: February 2, 2012
    Applicant: FOREST LABORATORIES HOLDINGS LTD.
    Inventors: Gary Samoriski, Nika Adham
  • PHARMACEUTICAL COMPOSITIONS CONTAINING DOPAMINE RECEPTOR LIGANDS AND METHODS OF TREATMENT USING DOPAMINE RECEPTOR LIGANDS
    Publication number: 20110015208
    Abstract: The present invention relates to pharmaceutical compositions containing dopamine receptor ligands and selective serotonin reuptake inhibitors and to methods of treating disorders such as schizophrenia, major depressive disorder and bipolar depression using combinations of dopamine receptor ligands and selective serotonin reuptake inhibitors. The present invention also relates to methods of treating depression using dopamine receptor ligands.
    Type: Application
    Filed: September 27, 2010
    Publication date: January 20, 2011
    Inventors: Gary Samoriski, Nika Adham
  • Combination of an NMDA receptor antagonist and a selective serotonin reuptake inhibitor for the treatment of depression and other mood disorders
    Publication number: 20100076073
    Abstract: The present invention provides a method for the treatment of depression, including treatment-resistant depression, and other mood disorders using a combination of an NMDA receptor antagonist and a SSRI that is citalopram or escitalopram. It has unexpectedly been shown that the combination has a synergistic and potentiated effect of either compound as monotherapy, resulting in an enhanced therapeutic effect at lower doses.
    Type: Application
    Filed: November 20, 2009
    Publication date: March 25, 2010
    Applicant: MERZ PHARMA GmbH & CO. KGaA
    Inventors: Sandeep Gupta, Gary Samoriski
  • METHODS OF TREATING CNS DISORDERS
    Publication number: 20090275597
    Abstract: The present invention relates to methods of treating various CNS disorders, e.g., mania, bipolar disorder and schizophrenia, by administering NMDA receptor antagonists, alone or in combination with dopamine receptor antagonists.
    Type: Application
    Filed: May 1, 2009
    Publication date: November 5, 2009
    Applicant: FOREST LABORATORIES HOLDINGS LIMITED
    Inventors: Kelly PAPADAKIS, Nika ADHAM, Gary SAMORISKI
  • PHARMACEUTICAL COMPOSITIONS CONTAINING DOPAMINE RECEPTOR LIGANDS AND METHODS OF TREATMENT USING DOPAMINE RECEPTOR LIGANDS
    Publication number: 20090036468
    Abstract: The present invention relates to pharmaceutical compositions containing dopamine receptor ligands and selective serotonin reuptake inhibitors and to methods of treating disorders such as schizophrenia, major depressive disorder and bipolar depression using combinations of dopamine receptor ligands and selective serotonin reuptake inhibitors. The present invention also relates to methods of treating depression using dopamine receptor ligands.
    Type: Application
    Filed: August 4, 2008
    Publication date: February 5, 2009
    Applicant: FOREST LABORATORIES HOLDINGS LIMITED
    Inventors: Gary SAMORISKI, Nika ADHAM
  • Combination of an NMDA receptor antagonist and a selective serotonin reuptake inhibitor for the treatment of depression and other mood disorders
    Publication number: 20050014743
    Abstract: The present invention provides a method for the treatment of depression, including treatment-resistant depression, and other mood disorders using a combination of an NMDA receptor antagonist and a SSRI that is citalopram or escitalopram. It has unexpectedly been shown that the combination has a synergistic and potentiated effect of either compound as monotherapy, resulting in an enhanced therapeutic effect at lower doses.
    Type: Application
    Filed: May 27, 2004
    Publication date: January 20, 2005
    Applicant: Forest Laboratories, Inc.
    Inventors: Sandeep Gupta, Gary Samoriski